Diacerein 1% ointment    (DrugBank: Diacerein)

2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
36表皮水疱症15
46悪性関節リウマチ0

36. 表皮水疱症 [臨床試験数:147,薬物数:170(DrugBank:40),標的遺伝子数:32,標的パスウェイ数:113
Searched query = "Epidermolysis bullosa", "EBS", "JEB", "DDEB", "RDEB", "Kindler syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
15 / 147 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-000439-29-GB
(EUCTR)
04/06/201822/03/2018A Multi-center Study to Evaluate How CCP-020 (Diacerein 1% ointment) is Absorbed in the Blood and Removed from the Body in Patients with Epidermolysis Bullosa (EB)A Multi-center Study to Evaluate the Pharmacokinetics of Diacerein and Rhein and the Safety of Diacerein after Maximum Use, Topical Administration of CCP-020 (Diacerein 1% ointment) to Patients with Epidermolysis Bullosa (EB) Epidermolysis Bullosa (EB)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: Diacerein
Product Code: CCP-020
INN or Proposed INN: DIACEREIN
Castle Creek Pharmaceuticals, LLCNULLNot RecruitingFemale: yes
Male: yes
4Phase 1United States;France;Netherlands;Germany;United Kingdom
2NCT03472287
(ClinicalTrials.gov)
May 18, 201814/3/2018To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)A Multi-Center Study to Evaluate the Pharmacokinetics of Diacerein and Rhein and the Safety of Diacerein After Maximum Use, Topical Administration of CCP-020 (Diacerein 1% Ointment) to Patients With Epidermolysis Bullosa (EB)Epidermolysis Bullosa (EB);Epidermolysis Bullosa Simplex;Dystrophic Epidermolysis Bullosa;Junctional Epidermolysis BullosaDrug: Diacerein 1% OintmentCastle Creek Pharmaceuticals, LLCNULLCompleted4 YearsN/AAll11Phase 1United States;France;Netherlands;United Kingdom
3EUCTR2017-003757-41-DE
(EUCTR)
19/04/201821/02/2018An International Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)An International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) Epidermolysis Bullosa Simplex (EBS)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: Diacerein
Product Code: Diacerein
INN or Proposed INN: DIACEREIN
Other descriptive name: Diacerein
Castle Creek Pharmaceuticals, LLCNULLNot RecruitingFemale: yes
Male: yes
80Phase 2United States;France;Austria;Australia;Israel;Netherlands;Germany;United Kingdom;Italy
4EUCTR2017-003757-41-NL
(EUCTR)
11/04/201806/12/2017An International Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)An International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) Epidermolysis Bullosa Simplex (EBS)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: Diacerein
Product Code: Diacerein
INN or Proposed INN: DIACEREIN
Other descriptive name: Diacerein
Castle Creek Pharmaceuticals, LLCNULLNot RecruitingFemale: yes
Male: yes
80Phase 2United States;France;Austria;Australia;Israel;Germany;Netherlands;United Kingdom;Italy
5EUCTR2017-003757-41-GB
(EUCTR)
19/02/201813/11/2017An International Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)An International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) Epidermolysis Bullosa Simplex (EBS)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: Diacerein
Product Code: Diacerein
INN or Proposed INN: DIACEREIN
Other descriptive name: Diacerein
Castle Creek Pharmaceuticals, LLCNULLNot RecruitingFemale: yes
Male: yes
80Phase 2United States;France;Austria;Australia;Israel;Netherlands;Germany;Italy;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2017-003757-41-FR
(EUCTR)
07/02/201817/10/2018An International Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)An International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) Epidermolysis Bullosa Simplex (EBS)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: Diacerein
Product Code: Diacerein
INN or Proposed INN: DIACEREIN
Other descriptive name: Diacerein
Castle Creek Pharmaceuticals, LLCNULLNot RecruitingFemale: yes
Male: yes
80Phase 2United States;France;Austria;Australia;Israel;Netherlands;Germany;United Kingdom
7EUCTR2017-003757-41-AT
(EUCTR)
04/01/201829/11/2017An International Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)An International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) Epidermolysis Bullosa Simplex (EBS)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: Diacerein
Product Code: Diacerein
INN or Proposed INN: DIACEREIN
Other descriptive name: Diacerein
Castle Creek Pharmaceuticals, LLCNULLNot RecruitingFemale: yes
Male: yes
84Phase 2France;United States;Australia;Austria;Israel;Netherlands;Germany;Italy;United Kingdom
8NCT03389308
(ClinicalTrials.gov)
December 1, 201719/12/2017Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa SimplexAn International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex (EBS)Epidermolysis Bullosa;Epidermolysis Bullosa SimplexDrug: diacerein 1% ointmentCastle Creek Pharmaceuticals, LLCNULLCompleted6 Months99 YearsAll51Phase 2United States
9EUCTR2016-004427-24-AT
(EUCTR)
10/10/201730/05/2017An International Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) [DELIVERS Study] Epidermolysis Bullosa Simplex (EBS)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Castle Creek Pharmaceuticals, LLCNULLNot Recruiting Female: yes
Male: yes
80Phase 2France;United States;Australia;Austria;Israel;Netherlands;Germany;Italy;United Kingdom
10EUCTR2016-004427-24-NL
(EUCTR)
06/09/201723/06/2017An International Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) [DELIVERS Study] Epidermolysis Bullosa Simplex (EBS)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Castle Creek Pharmaceuticals, LLCNULLNot Recruiting Female: yes
Male: yes
80Phase 2France;United States;Austria;Australia;Israel;Germany;Netherlands;Italy;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2016-004427-24-DE
(EUCTR)
24/08/201723/05/2017An International Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) [DELIVERS Study] Epidermolysis Bullosa Simplex (EBS)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Castle Creek Pharmaceuticals, LLCNULLNot Recruiting Female: yes
Male: yes
80Phase 2France;United States;Austria;Australia;Israel;Netherlands;Germany;Italy;United Kingdom
12EUCTR2016-004427-24-GB
(EUCTR)
21/07/201706/07/2017An International Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) [DELIVERS Study] Epidermolysis Bullosa Simplex (EBS)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: Diacerein
Product Code: Diacerein
INN or Proposed INN: DIACEREIN
Other descriptive name: Diacerein
Castle Creek Pharmaceuticals, LLCNULLNot RecruitingFemale: yes
Male: yes
80Phase 2France;United States;Austria;Australia;Israel;Netherlands;Germany;Italy;United Kingdom
13NCT03154333
(ClinicalTrials.gov)
June 1, 201710/5/2017Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa SimplexEpidermolysis Bullosa SimplexDrug: diacerein 1% ointment;Drug: A placebo ointmentCastle Creek Pharmaceuticals, LLCNULLTerminated4 YearsN/AAll54Phase 2United States;Australia;Austria;France;Germany;Israel;Netherlands;United Kingdom
14EUCTR2018-000439-29-NL
(EUCTR)
27/09/2018A Multi-center Study to Evaluate How CCP-020 (Diacerein 1% ointment) is Absorbed in the Blood and Removed from the Body in Patients with Epidermolysis Bullosa (EB)A Multi-center Study to Evaluate the Pharmacokinetics of Diacerein and Rhein and the Safety of Diacerein after Maximum Use, Topical Administration of CCP-020 (Diacerein 1% ointment) to Patients with Epidermolysis Bullosa (EB) Epidermolysis Bullosa (EB)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: Diacerein
Product Code: CCP-020
INN or Proposed INN: DIACEREIN
Castle Creek Pharmaceuticals, LLCNULLNAFemale: yes
Male: yes
20Phase 1France;United States;Germany;Netherlands;United Kingdom
15EUCTR2016-004427-24-FR
(EUCTR)
21/08/2017An International Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) Epidermolysis Bullosa Simplex (EBS)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Castle Creek Pharmaceuticals, LLCNULLNot Recruiting Female: yes
Male: yes
80Phase 2United States;France;Austria;Australia;Israel;Netherlands;Germany;United Kingdom

46. 悪性関節リウマチ [臨床試験数:4,183,薬物数:2,538(DrugBank:401),標的遺伝子数:183,標的パスウェイ数:219
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.
0 / 4,183 trial found